Using Actiwatch to monitor circadian rhythm disturbance in Huntington’ disease: A cautionary note  by Townhill, Jenny et al.
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a  b  s  t  r  a  c  t
Huntington’s  disease  (HD)  is an  inherited  neurodegenerative  disorder  that  is  well  recognised  as  producing
progressive  deterioration  of motor  function,  including  dyskinetic  movements,  as  well  as  deterioration
of  cognition  and  ability  to  carry  out  activities  of  daily  living.  However,  individuals  with  HD  commonly
suffer  from  a wide  range  of  additional  symptoms,  including  weight  loss  and  sleep  disturbance,  possibly
due  to disruption  of  circadian  rhythmicity.  Disrupted  circadian  rhythms  have  been  reported  in mice
models  of  HD and  in humans  with  HD.  One way  of assessing  an individual’s  circadian  rhythmicity  in  a
community  setting  is  to  monitor  their  sleep/wake  cycles,  and  a convenient  method  for  recording  periods
of  wakefulness  and  sleep  is  to use  accelerometers  to discriminate  between  varied activity  levels  (including
sleep)  during  daily  life. Here  we used  Actiwatch® Activity  monitors  alongside  ambulatory  EEG and  sleep
diaries  to  record  wake/sleep  patterns  in  people  with HD  and  normal  volunteers.  We  report  that  periods
of  wakefulness  during  the  night,  as  detected  by activity  monitors,  agreed  poorly  with  EEG  recordings  inuntington’s disease HD subjects,  and  unsurprisingly  sleep  diary  ﬁndings  showed  poor  agreement  with  both  EEG recordings
and  activity  monitor  derived  sleep  periods.  One  explanation  for this  is the  occurrence  of  ‘break  through’
involuntary  movements  during  sleep  in  the  HD  patients,  which  are  incorrectly  assessed  as  wakeful  periods
by the  activity  monitor  algorithms.  Thus,  care  needs  to be  taken  when  using  activity  monitors  to  assess
circadian  activity  in  individuals  with  movement  disorders.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
Huntington’s disease (HD) is a progressive neurodegenerative
isorder presenting in midlife with a triad of motor, emotional and
ognitive symptoms (Walker, 2007). It is well established that the
utation causing HD affects the central nervous system, in partic-
lar, the medium spiny neurons of the striatum (Estrada Sánchez
t al., 2008). The motor disorder is most widely known for the
haracteristic and striking involuntary movements, in particular
horea and dystonia, but the cognitive decline and emotional dis-
urbance are often more debilitating. Moreover, there are a range
∗ Corresponding author at: The Cardiff University Brain Repair Group, Life Sciences
uilding, School of Biosciences, Museum Avenue, Cardiff CF10 3AX, United Kingdom.
el.: +44 2920875188.
E-mail address: rosserae@cf.ac.uk (A.E. Rosser).
ttp://dx.doi.org/10.1016/j.jneumeth.2016.01.009
165-0270/© 2016 The Authors. Published by Elsevier B.V. This is an open access article uof other symptoms such as weight loss and sleep disturbance that
are commonly reported in HD and can be difﬁcult to manage. Sleep
disturbance can be distressing for both patients and carers, may
exacerbate the cognitive decline, and is also reported in many other
progressive neurodegenerative disorders such as Parkinson’s dis-
ease (PD) and Alzheimer’s disease (AD) (Aziz et al., 2010; Raggi et al.,
2013; Slats et al., 2013). Sleep disturbance in HD has been reported
as occurring very early in the course of the disease in both ani-
mal  and human studies and is temporally associated with cognitive
deterioration (Lazar et al., 2015; Lebreton et al., 2015). It is a dis-
ruptive symptom for both affected individuals and their carers and
currently is by necessity treated empirically and often with little
success (Morton, 2013). Although there is some evidence of degen-
eration of the hypothalamus in HD individuals (Van Wamelen et al.,
2013; Hult et al., 2010) and evidence of lowered melatonin levels
(Kalliolia et al., 2014) the mechanism underlying circadian rhyth-
micity disruption and sleep disturbance are still unclear and need
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1 roscie
t
2
H
t
n
e
d
a
i
(
a
m
(
s
w
g
i
e
t
i
a
s
p
a
e
o
s
w
o
t
a
i
2
a
s
A
n
t
t
o
w
(
t
2
2
W
r
a
t
T
E4 J. Townhill et al. / Journal of Neu
o be elucidated in order to develop effective treatments (Morton,
013).
There is evidence that both mouse and rat transgenic models of
D can recapitulate sleep disorders reported in patients, making
hem potentially important means for understanding the mecha-
isms underlying circadian disruption and sleep disturbance. For
xample, the circadian behaviour of R6/2 mice was  found to be
isturbed, with increased daytime and reduced nocturnal activity
long with disruption of circadian clock genes (mPer2 and mBmal1)
n the suprachiasmatic nuclei (SCN), motor cortex and striatum
Morton et al., 2005). A relationship between circadian disruption
nd cognitive decline in R6/2 HD mice was inferred when the phar-
acological imposition of sleep and wakefulness with Alprazolam
Pallier et al., 2007) and Modaﬁnil (Pallier and Morton, 2009) was
hown to improve cognitive function in the mutant animals. Less
ork has been done in transgenic rat models, although a trans-
enic rat model of HD mirrors the sleep-wake disturbances seen
n the mice, with accompanying reduction in the levels of adren-
rgic 2 receptors and leptin (Bode et al., 2009). The capacity to
ranslate between human and rodent studies is important in facil-
tating understanding of the biology of circadian disruption in HD,
nd a number of techniques have been employed to investigate
leep architecture in HD patients and rodents, with polysonogra-
hy being recognised as the gold standard with EEG as a necessary
nd important element of this. However, full polysonography, or
ven simple ambulatory EEG, are cumbersome, difﬁcult to perform
ver prolonged periods of time for technical and acceptability rea-
ons, and relatively expensive. Thus, there have been attempts use
earable devices such as Actiwatch® to assess movement over
ne or more 24 h periods as a surrogate for sleep on the basis
hat individuals tend to move substantially more when they are
wake than asleep. Indeed Actiwatch® technology has been used
n a number of HD circadian and sleep studies (Hurelbrink et al.,
005; Morton et al., 2005; Kantor et al., 2013) and could represent
 simple and acceptable way of recording circadian rhythm and
leep in both people and animal models of HD. Here we compare
ctiwatch® recording, ambulatory EEG and sleep diaries in small
umbers of HD individuals as a prelude to developing a transla-
ional platform to assess circadian disruption in this disorder. While
he gold standard for sleep analysis is polysomnography (PSG), in
ur study we adapted and conﬁned the test to EEG recording as we
ere interested in differentiating between wakefulness and sleep
rather than sleep scoring) this was considered sufﬁcient and found
o be pragmatic.
. Materials and methods
.1. Study population
Thirteen participants were recruited to this study from the South
ales Huntington’s disease clinic, based in Cardiff. Inclusion crite-
ia included a positive genetic test for HD, being above the age of 18
nd below the age of 65, and having no concomitant medical condi-
ions. Asymptomatic individuals were deﬁned as having a Uniﬁed
able 1
xperimental patient and control demographics.
Factor Symptomatic HD patients (N
Mean age (range) in years 51.8 (29–64) 
Gender M:F  6:3 
CAG  repeat length (range) 44 (41–52) 
Age  of onset 44.1 years 
UHDRS total motor score (mean, range) 42.9 (28–72) 
UHDRS chorea score (mean, range) 11.1 (5–20) 
UHDRS total function capacity (mean, range) 7.6 (4–11) 
BMI  21.6 (range 17.5–31.3) nce Methods 265 (2016) 13–18
Huntington’s Disease Rating Scale (UHDRS) total functional score
(TFC) of 13/13 and an UHDRS motor score of less than 6 (n = 4),
and symptomatic individuals having a TFC between 4 and 11 and
a total motor score greater than 20 (n = 9). Assessment of disease
status (UHDRS motor and functional scores) were undertaken by
an experienced neurologist. Nine community control individuals
were recruited. The demographics of the study participants are
summarised in Table 1. In the presymptomatic group, one patient
was on oral contraceptive and one on buproprion. Of the symp-
tomatic patients, one was on an anti-psychotic, olanzapine, one
on an antidepressant, two were on hypnotics, one on asprin and
another on aspirin and ibroprofen. In the presymptomatic group
there were 2 ex-smokers and 1 non-smokers. In the symptomatic
group there were 2 ex-smokers, 1 smoker and 6 non-smokers. One
symptomatic patient had a history of previous alcohol abuse and
alcohol history was  unremarkable for all other participants. No
subjects had respiratory comorbidities.
Ethical approval for the study was  obtained from the South East
Wales local research ethics committee (08/WSE02/10) and patients
were recruited from the Cardiff Huntington’s disease clinic. All
diagnoses were conﬁrmed with a positive genetic test. Controls
were healthy volunteers who were not at risk of HD. All individ-
uals recruited into the study were asked to wear ambulatory EEGs
for a 24 h period, to wear an Actiwatch® and to keep a sleep diary
for a period of one week, and to donate saliva samples for cortisol
measurement.
The Actiwatch® Activity monitoring system (Cambridge Neu-
rotechnology Ltd) was worn on the non-dominant hand and
recorded activity over a period of seven days. Actiwatch records
with a sensitivity of 0.05 g with a bandwidth between 3 Hz and
11 Hz and a sampling frequency of 32 Hz. 1 min  epochs were
put into 5 min  bins for comparison with EEG. The Actiwatches®
employed an analogue that used the amount of activity (number of
movements per epoch, and number of movements above a prede-
ﬁned threshold) to make an estimate as to whether the subject was
awake or asleep. All sleep episodes were visually inspected before
analysis to screen for artefacts and malfunctioning. The watches
were waterproof and participants were asked to wear them con-
tinuously. Patients were instructed to press the activation button,
which delivered a single recorded pulse, to indicate the time they
started to try to sleep and to press again to indicate waking in the
morning.
EEG electrodes were ﬁxed with collodion and placed accord-
ing to the 10/20 international system. The continuous recording
was obtained using ambulatory EEG (XLTEK) system worn for 24 h.
The date and time were synchronised for analysis of EEGs and
Actiwatch® data. The EEG traces were analysed ofﬂine by an expe-
rienced neurophysiologist.
The EEG was scored manually in epochs of ﬁve minute to
determine wakefulness or sleep. The criteria for wakefulness was
denoted by presence of eyeblinks artefacts, and/or an alpha rhythm
in the EEG. Early sleep stage was  characterized by lack of eye-
blink artefacts, fragmentation or absence of alpha activity and
replacement of background EEG by low amplitude mixed frequency
 = 9) Asymptomatic HD patients (N = 4) Controls (N = 9)
44 (29–56) 41.9 (27–56)
1:3 3:6
40 (38–41) N/A
N/A N/A
0.3 (0–1) N/A
0 N/A
13 (13–13 a) N/A
27.1 (range 20.6–34.5)
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oig. 1. Sleep diary analysis. Analysis of sleep diary data in control, HD asymptoma
lthough the trends may  indicate a value for sleep diaries with larger group numbe
EG activity and presence of slow eye movements. Later stages
f sleep were identiﬁed by characteristic sleep phenomena such
s vertex waves, K complexes, sleep spindles and slow waves.
ifferentiation between REM (rapid eye movement) sleep and
akefulness was determined by lack of eyeblink artefacts, absence
f sustained alpha activity and presence of rapid eye movement
rtefacts.
Patients were given sleep diaries in the form of a booklet with a
eries of questions for each 24 h period. They were encouraged to
ake entries into the diary throughout the day with an emphasis
n collecting information about night time sleep as soon as possible
fter rising in the morning. The questions included: time of going to
ed at night; time the subject started trying to go to sleep; approx-
mately how long it took them to fall asleep; how many times they
oke in the night and the duration of the wakeful period; the time
hey woke in the morning; the time they rose in the morning; the
umber and duration of day time naps.All participants collected saliva twice a day, 12 h apart (080.00
nd 20.00), for a week by collecting saliva in microcentrifuge tubes.
ubjects were requested to collect at least 1 ml  of saliva (to a mark
n the tube). Samples were stored at −20 ◦C until analysis of cortisold HD symptomatic individuals. No statistically signiﬁcant differences were found,
 error bars represent standard errors of the mean.
levels could be performed by Prof J Herbert and S Cleary (University
of Cambridge).
3. Statistics
All ANOVA were undertaken using the Genstat v16.1 statisti-
cal package, with unbiased iterative correction for missing values.
Comparison of epochs of Actiwatch® wakefulness with EEG and
sleep diaries was performed visually on a patient-by-patient basis.
4. Results
4.1. Sleep diaries
Of the 22 participants who  took part in the study, 21 completed a
sleep diary. There was a trend for deterioration across most param-
eters with more advanced disease state (Fig. 1A–F), in particular for
sleep latency, number and duration of wakeful periods in the night,
and number and duration of day time naps, but not for time of
ﬁrst attempting night-time sleep. However, when the groups were
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ompared by 2-way ANOVA none of the differences reached signif-
cance on any of the parameters.
.2. Actiwatch® recordings
There was some loss of data caused by water damage due to
aulty waterprooﬁng of some watches. Analysis of Actiwatch® data
y group (pre-symptomatic vs symptomatic vs controls) to assess
ifferences in circadian rhythmicity did not reveal any signiﬁ-
ant group differences. The periods of wakefulness as assessed by
ctiwatch® were then directly compared to EEG and sleep diary
ata on a patient-by-patient basis (see Fig. 2).
.3. Comparison of sleep diaries, Actiwatch® and EEG recordings
As the EEG was ﬁtted for the ﬁrst 24 h of the 7 day experi-
ent, the results obtained from the three different methods were
ompared over the ﬁrst 24 h to assess the consistency between
hem in measuring sleep disturbance. For three of the symp-
omatic individuals both full Actiwatch® and EEG data was not
vailable and so they were not included in the analysis. Across all
roups, the sleep diary had a tendency to fail to capture night-time
aking as recorded by the EEG. All periods of sleep as deter-
ined by Actiwatch® agreed with the EEG recording. However, for
oth symptomatic (Fig. 2) and asymptomatic (Fig. 3) HD subjects,
eriods of night-time wakefulness recorded by the Actiwatch®
greed poorly with EEG recordings in that there were multiple
eriods of ‘wakefulness’ indicated by the Actiwatch® for which the
orresponding period of EEG recording demonstrated the individ-
al to be asleep. This was not the case for all patients: in patient
 (with 4 periods of waking) and patient 10 (with 2 periods of
aking) there was agreement with the EEG recording. Some of
hese epochs were characterised by excessive movement artefact,
nd these are indicated in the ﬁgure as “sleep plus movement”.
here was one period of wakefulness recorded by the Actiwatch®
hat corresponded with a recording of awake in the sleep diary
nd sleep plus movement on the EEG (patient 7). This may  indi-
ate that the EEG recording of this epoch does not reliably indicate
leep, although this patient was noted to have completed the
iary unreliably. Unfortunately a full data set was only available
or one control patient (due to Actiwatch® failure and shortage
f EEG monitors for use in controls). In that subject there were
wo periods of Actiwatch® waking; one associated with “sleep plus
ovement” on the EEG and one also recorded as wakefulness by
he EEG.
.4. Cortisol
Saliva samples were obtained for all 4 asymptomatic, 6 of the 9
ymptomatic, and all nine control individuals. There were miss-
ng samples across the 7 days in many cases, and indeed only
ne of the controls produced a complete set of samples. Missing
alues were corrected by an iterative unbiased estimator rou-
ine within the analyses of variance package (Genstat v16.2, VSN
nternational, Oxford). On direct questioning, many subjects of
oth the HD affected and control groups reported that they found
aliva collection mildly unpleasant and also the required amount of
aliva. Analysis of cortisol levels revealed no differences between
roups (F2,18 = 2.99, p < 0.076), but a difference in time (F1,16 = 172.8,
 < 0.001) with morning cortisol levels being higher than in the
vening, and a signiﬁcant group × time interaction (F2,18 = 3.74,
 < 0.05), with a blunted cortisol peak in HD symptomatic subjects
see Fig. 1G).nce Methods 265 (2016) 13–18
5. Discussion
By using three methods to monitor sleep in HD patients, this
study highlights the potential shortcomings in diary and actime-
try records, in comparison to the more intensive ambulatory EEG
approach. The main ﬁnding in this study was that ambulatory
EEG recordings suggested that caution should be applied when
interpreting Actiwatch® recording in individuals with both asymp-
tomatic and symptomatic HD. Speciﬁcally, although there was
good agreement when the Actiwatches® indicated sleep, and there
were periods in which both Actiwatches® and EEG demonstrated
the individual to be awake, there were also multiple occasions
when the Actiwatch® indicated wakefulness but the EEG indi-
cated that the patients was asleep. This was the case even in
those periods in which sleep recordings punctuated with move-
ment artefact were excluded. Thus, in these cases recording with
Actiwatches® alone would overestimate the extent of wakefulness,
even in asymptomatic subject with little day time chorea, which
could consequently interfere with assessment of circadian rhyth-
micity. The most likely reason for this discrepancy is that, despite
the fact that most involuntary movements in HD disappear with
sleep, people with HD nevertheless display involuntary movements
during lighter periods of sleep (Fish et al., 1991), and these are more
exaggerated than sleep-associated movement in control individ-
uals and are thus recorded as wakeful by the Actiwatch® algorithm.
Thus, caution is necessary in interpreting Actiwatch® assess-
ment of wake/sleep cycles in individuals with movement disorders.
It is possible that this could be addressed by adjustments to the
technology calibration or to its placement (for example place-
ments on the trunk could be more reliable), but our data suggests
that such technology would need to be veriﬁed by EEG recordings
before it could be reliably used independently in assessment of
wake/sleep cycles. It is unlikely that these limitations would apply
to rodent models of HD in the same way, since overt dyskinetic
movements such as chorea and tics are generally not seen in HD
animals although they may  exhibit generalised akinesias, hyperac-
tivity and abnormal gait and postural responses. However, our data
also indicates that simultaneous Actiwatch® and ambulatory EEG
could be useful in the study of nocturnal involuntary movements.
The sleep diary tended to underestimate the extent of wake-
ful periods as recorded by the EEG and this was especially obvious
in the symptomatic individuals. Discrepancies in diary recordings
and other methods of sleep recording, including accelerometers,
have been reported previously, although in healthy populations
it appears that there is a tendency for more sleep disturbance to
be reported by diary than is recorded by accelerometers (Kawada,
2008; Short et al., 2012). The under-reporting of EEG-conﬁrmed
wakeful periods in our study suggests that individuals do not ﬁll
in the diary during a wakeful period and either fail to complete
or fail to remember the wakeful period the following morning.
However, there were trends towards worse night-time sleep and
increased day-time napping in HD positive individuals, which may
have reached signiﬁcance on a group basis with larger numbers.
Thus, sleep diaries may  still have a useful contribution in this con-
text but, from our data, do not appear to be reliable on an individual
basis.
All groups exhibited the expected circadian changes in sali-
vary cortisol levels with morning levels signiﬁcantly higher than
evening levels, indicating that the daily cycles of all subjects were
intact. However, we also saw blunting of the morning level in symp-
tomatic individuals. Previous reports have most commonly found
cortisol levels to be raised in HD (Aziz et al., 2009; Saleh et al.,
2009), although this was not replicated in a recent study in which
24 h sampling of asymptomatic and symptomatic HD patients was
performed (Kalliolia et al., 2015). Kalliolia et al. suggested that
the raised levels in previous studies could be due to the stress of
J. Townhill et al. / Journal of Neuroscience Methods 265 (2016) 13–18 17
a 
Pa
e
nt
 2
   
   
   
   
  P
a
en
t 1
 
Time  23 .55-00.25  02 .20-02.30  03 .15-03.35  04 .50-05.05  
Acwatch Awa ke Aw ake Awa ke Awa ke 
EEG Awake  Awake Awake Awake 
DIARY sleep   sleep   sleep   sleep 
Time s 01 .00-01.10  01 .35-01.40  06 .40-06.50  
Acwatch Awak e  Awake  Awake 
EEG S+M S+M S+M 
DIARY slee p slee p sleep 
Pa
e
nt
 4
   
   
   
   
 P
a
en
t 3
 Time s 23 .40-23.55  00 .35-00.50  02 .25-02.45  03 .00-03.10  03 .15-03.55  05 .50-06.05  06 .10-06.25  06 .35-06.55  08 .40-09.10  
Acwatch Awak e  Awake  Awake  Awake Awak e Awak e Aw ake Aw ake Aw ake 
EEG Awake  Sleep S+ M Sleep S+M Sleep Sleep Sleep Awake 
DIARY sleep   sleep   sleep   sleep sleep  sleep  sleep  sleep  sleep 
Time s 23 .20-23.35  00 .05-00.15  01 .15-01.25  01 .30-02.30  03 .14-03.55  06 .10-06.25  06 .40-07.10  
Acwatch Awak e  Awake  Awake Aw ake Aw ake Aw ake Aw ake 
EEG S+M Sleep Sleep  Awake S+ M Awake Awake 
DIAR Y Did no t ﬁll in diary 
Pa
e
nt
 6
   
   
   
   
   
  P
a
en
t 5
 ` 23 .40-00.20  00 .55-01.10  01 .30-01.45  02 .05-02.15  02 .25-02.40  04 .00-04.15  04 .50-05.00  05 .10-05.20  
Acwatch Awak e  Awake  Awake Awake Aw ake Awa ke Awa ke Awa ke 
EEG S+M Sleep S+ M Sleep S+M Slee p S+M Slee p 
DIARY sleep   sleep   sleep   sleep sleep  Slee p sleep  Slee p 
Time s 02 .20-02.40  04 .30-04.50  05 .05-05.55  
Acwatch Awak e  Awake  Awake 
EEG S+M S+M  Sleep 
DIARY slee p slee p sleep 
b 
Pa
e
nt
 8
   
   
   
   
   
   
   
  P
a
en
t 7
 Time s 02 .50-03.00  03 .25-03.45  04 .20-04.30  
Acwatch Awak e Awak e Awak e 
EEG S+M Sleep Sleep 
DIARY  Awak e  sleep sleep 
Times 00 .35-00.45  04 .40-04.50  
Acwatch Awak e Awak e 
EEG Sleep Sleep 
DIA RY  Unreli abl y complete d 
Pa
e
nt
 1
0 
   
   
   
   
   
   
Pa
e
nt
 9
 Time s 23 .25-23.40  23 .45-23.55  02 .40-02.50  03 .15-03.25  04 .10-04.25  05 .20-05.30  05 .40-06.15  
Acwatch Awak e Awak e Awake Aw ake Aw ake Aw ake Aw ake 
EEG Slee p Slee p Slee p Sleep Awake  Sleep  Sleep 
DIARY  slee p slee p sleep  sleep  sleep   sleep   sleep 
Times 06 .15-06.25  06 .55-07.05  
Acwatch Awak e Awak e 
EEG Awake Awake 
DIARY  Awak e  sleep 
Fig. 2. Periods of wakefulness as indicated by Actiwatch recordings in the six HD symptomatic individuals (a) and four asymptomatic individuals (b) in whom both recordings
were  available, along with at least one night recording in the sleep diary. No periods were seen in which the Actiwatch recorded sleep and the EEG recorded awake. Conversely,
there  were multiple periods when the Actiwatch recorded wakefulness that corresponded with “sleep” or “sleep plus movement artefact’ on the EEG (period of Actiwatch
and  EEG agreement in light grey and disagreement in dark grey). There is one period (patient 7) where the Actiwatch and sleep diary agree and the EEG recording has been
i tefact
r
t
a
c
anterpreted as sleep plus movement. Abbreviations: S + M = sleep plus movement ar
epeated sampling. The blunted levels in this study may  be indica-
ive of circadian disruption, but currently remain unexplained and
re deserving of further study in a larger cohort of patients. Salivary
ortisol has been used in numerous studies to assay cortisol levels
nd appears to correlate well with serum levels (Gallagher et al.,.
2006). There were some problems of acceptability in that some
individuals found the collection method distasteful, some patients
reported difﬁculty in producing enough saliva to ﬁll the tube to the
1 ml  mark, and there were missing samples across the 7 day collec-
tion period. However, overall this appears to be a feasible method
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or collecting community based samples with relatively little asso-
iated stress for the study subjects, as has been noted previously in
lzheimer’s disease (Hatﬁeld et al., 2004).
In summary, we highlight some of the difﬁculties in attempting
o undertake community-based studies of circadian rhythm and
leep in an HD population. In addition to technical difﬁculties that
ncluded loss of data due to equipment failure, we  found poor
greement between Actiwatch® and ambulatory EEG recordings
or patients with both asymptomatic and symptomatic HD, which
e interpret as most likely to be due to involuntary movement
breakthrough” during sleep. The data presented in our study is not
ufﬁcient to suggest the absence of circadian disturbance in HD, and
ndeed we consider that the accumulating animal and clinical data
oint towards circadian disturbance being an intrinsic element of
his disorder. However, we believe the ﬁndings are important to
onsider when designing studies of circadian activity and sleep in
D and also in other disorders in which involuntary movements
re a feature. We  could not conﬁrm the usefulness of sleep diaries
rom our study, but have data to support further assessment of
aliva samples for the assessment of cortisol in this condition.
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